FDA to Pull the Plug on Avastin for Metastatic Breast Cancer

A cancer drug fast-tracked for approval by the FDA in 2008 for the treatment of metastatic breast cancer will have that approval revoked, the agency announced yesterday. The decision follows the recommendation by an expert panel in July that voted 12-1 to reverse the approval of Avastin for metastatic breast cancer.

Contact our Personal Injury Attorneys if you have experienced the negative effects of Avastin.

Leave a Reply

You must be logged in to post a comment.